AI4S company "Aurora Star Journey" secures over 100 million yuan in Series A financing to build bio-intelligent infrastructure | Exclusive by 36Kr

36Kr learned that the AI for Science company "Aoming Xingcheng" recently completed a strategic Series A financing of over 100 million yuan. The investors in this round include several leading investment institutions, industrial chain leaders, and state - owned assets from multiple regions, such as Shenzhen Capital Group, Fosun Pharma (Fujian Capital), Taiping Equity, Guangdong Traditional Chinese Medicine and Big Health Fund, and Hangshi Group. Meanwhile, the company has also established a deep cooperation mechanism for achievement transformation with several world - class scientific research institutions, including Shenzhen Bay Laboratory, forming a full - chain layout covering technology R & D, clinical application, and industrial ecosystem empowerment.

The year 2025 is regarded as a watershed for the development of AI4S. With the emergence of general scientific research engines and the NVIDIA GTC Conference listing AI4S, large language models, and embodied intelligence as the three core directions of artificial intelligence, global capital and technological resources are accelerating their aggregation into this field. However, most current AI applications in scientific exploration still remain at the level of "result fitting", with a gap in the ability to understand mechanisms and define problems.

The core goal of Aoming Xingcheng is to achieve a leap from "results to mechanisms" and from "solving problems to formulating problems". Lin Ziao, the founder and CEO of the company, believes that Aoming Xingcheng "is not simply improving the accuracy of models and agents, but is committed to building an AI scientist's ability system".

Specifically, the company will focus on breakthroughs in three aspects: First, enabling AI to move from "representation learning" to "mechanism modeling", not only predicting results but approaching the internal logic of disease occurrence and development; Second, endowing AI with "problem - defining ability", enabling it not only to answer questions but also to identify key variables in complex systems and assist in formulating more valuable scientific questions; Third, enabling AI to form "exploratory reasoning ability", supporting the integrated scientific research process from hypothesis generation to path deduction. In the long run, this system is expected to evolve into a "medical AGI" for the entire life process.

To achieve this goal, Aoming Xingcheng has assembled a team with academic and industrialization backgrounds. The company was co - founded by three young Chinese scientists who returned from Harvard. Lin Ziao, the founder, holds dual doctorates in computational science and biomedicine from Harvard University and is the only Chinese doctoral graduate of Professor Gad Getz, the initiator of international cancer genomics research projects (such as TCGA, ICGC, and PCAWG). Co - founders Zhao Hanchen and Hao Jin also have Harvard doctoral backgrounds and are deeply involved in the intersection of artificial intelligence and emerging biotech.

Currently, Aoming Xingcheng has achieved a technological breakthrough in obtaining multi - dimensional omics information at low cost through its self - developed large AI model. It has built a bio - intelligent infrastructure based on the technological ecological closed - loop of "data - large model - agent" and developed an agent matrix covering multiple fields such as disease screening, new drug R & D, health management, and public health.

In its initial application scenario, the company has targeted disease screening with clear clinical pain points. Taking breast cancer as an example, traditional ultrasound and mammography screening have limitations such as a high missed - diagnosis rate (over 50%) in dense breasts and dependence on doctors' experience. The detection rate and specificity of existing liquid biopsy methods (such as ctDNA mutation and methylation) in early - stage populations are also not satisfactory.

In response to these problems, Aoming Xingcheng has developed several multi - disease screening agents based on cfDNA fragmentomics and large AI models, such as the breast cancer screening agent: OS - TuFEst - BRCA and its supporting kits. According to the company, this product only requires one tube of blood to simultaneously achieve ultra - early screening, accurate molecular typing, and ultra - sensitive prediction of axillary lymph node metastasis. Its early - screening sensitivity reaches 92% - 95%, and the recognition rate of cases missed by imaging is 96.2%.

In terms of clinical effects, the product achieves a 97.6% negative prediction rate for lymph node metastasis. This means that this technology is expected to assist doctors in clinical evaluation, help patients avoid unnecessary axillary surgeries, and achieve more precise "down - staging" treatment. Currently, the relevant results have been published in "Nature Communications" and have received support from multiple national science and technology major projects.

In addition, its core capabilities (OS - TuFEst®, multi - disease screening products) have also been endorsed by national authoritative institutions. In the "Expert Consensus on Multi - cancer Joint Screening Based on Liquid Biopsy Technology (2025 Edition)" recently led by the National Cancer Center, the analysis method combining multi - omics data and AI has received a "strong recommendation". The consensus also mentions that the TuFEst® technology has certain innovative value in reducing experimental costs and improving the sensitivity and specificity of pan - cancer detection.

The combination of AI4S and healthcare is essentially a competition of systematic capabilities in data, models, clinical practice, and industry. Compared with the traditional model that relies on high - cost experiments, Aoming Xingcheng's strategy of predicting multi - dimensional information based on large AI models has significantly reduced the cost of single - sample detection and data acquisition. Currently, the company has cooperated with over 50 top - tier hospitals and more than 100 physical examination institutions in China, laying a foundation for a clinical cooperation network to accumulate high - quality, high - standard, and large - scale real - world data.

Lin Ziao said that AI4S is essentially a "capability engine" that needs to be deeply integrated with the ecosystem. At present, Aoming Xingcheng has established strategic partnerships with institutions such as the Shenzhen Academy of Medical Sciences, Shenzhen Bay Laboratory, and the National Cancer Center. Its platform capabilities are accelerating their opening to the upstream and downstream of the large - health industrial chain, such as hospitals, pharmaceutical companies, and insurance companies, in order to achieve large - scale accessibility of cutting - edge medical technologies.